{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:29:10Z","timestamp":1787887750422,"version":"build-2784847793"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40121-024-01082-2","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:02:29Z","timestamp":1735574549000},"page":"99-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Respiratory Virus Vaccines: Pathways to Recommendations and Enhanced Coverage for At-Risk Populations"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0453-8663","authenticated-orcid":false,"given":"Stefania","family":"Maggi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"1082_CR1","unstructured":"United Nations. World Social Report 2023: leaving no one behind in an ageing world. 2023. https:\/\/desapublications.un.org\/publications\/world-social-report-2023-leaving-no-one-behind-ageing-world."},{"issue":"2","key":"1082_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/21645515.2020.1780847","volume":"17","author":"SE Talbird","year":"2021","unstructured":"Talbird SE, La EM, Carrico J, Poston S, Poirrier JE, DeMartino JK, et al. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum Vaccin Immunother. 2021;17(2):332\u201343.","journal-title":"Hum Vaccin Immunother"},{"key":"1082_CR3","unstructured":"Centers for Disease Control and Prevention. Background for CDC\u2019s Updated Respiratory Virus Guidance 2024, updated March 1, 2024. https:\/\/www.cdc.gov\/respiratory-viruses\/background\/index.html#print."},{"key":"1082_CR4","unstructured":"World Health Organization. Influenza (Seasonal) 2023. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal)."},{"key":"1082_CR5","unstructured":"Centers for Disease Control and Prevention. Respiratory Syncytial Virus Infection (RSV) RSV in Older Adults and Adults with Chronic Medical Conditions 2024, updated March 1, 2024. https:\/\/www.cdc.gov\/rsv\/high-risk\/older-adults.html."},{"key":"1082_CR6","unstructured":"Centers for Disease Control and Prevention. COVID-19 Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals 2023, updated February 9, 2023. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinical-care\/underlyingconditions.html."},{"issue":"11","key":"1082_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.34147","volume":"4","author":"S Magesh","year":"2021","unstructured":"Magesh S, John D, Li WT, Li Y, Mattingly-App A, Jain S, et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. JAMA Netw Open. 2021;4(11):e2134147.","journal-title":"JAMA Netw Open"},{"key":"1082_CR8","unstructured":"World Health Organization. Keeping Safe from COVID-19, Influenza, and Respiratory Syncytial Virus (RSV) This Autumn and Winter. Protecting Lives. Strengthening Health Systems 2023; cited February 20, 2024. https:\/\/www.who.int\/europe\/news-room\/events\/item\/2023\/09\/29\/default-calendar\/keeping-safe-from-covid-19--influenza--and-respiratory-syncytial-virus-(rsv)-this-autumn-and-winter.-protecting-lives.-strengthening-health-systems."},{"issue":"5","key":"1082_CR9","doi-asserted-by":"publisher","first-page":"2055422","DOI":"10.1080\/21645515.2022.2055422","volume":"18","author":"I Kolobova","year":"2022","unstructured":"Kolobova I, Nyaku MK, Karakusevic A, Bridge D, Fotheringham I, O\u2019Brien M. Vaccine uptake and barriers to vaccination among at-risk adult populations in the US. Hum Vaccin Immunother. 2022;18(5):2055422.","journal-title":"Hum Vaccin Immunother"},{"key":"1082_CR10","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3389\/fmicb.2020.01526","volume":"11","author":"CMC Rodrigues","year":"2020","unstructured":"Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol. 2020;11:1526.","journal-title":"Front Microbiol"},{"key":"1082_CR11","unstructured":"Centers for Disease Control and Prevention. Vaccination Trends\u2014Adults 2024. https:\/\/www.cdc.gov\/respiratory-viruses\/data-research\/dashboard\/vaccination-trends-adults.html."},{"key":"1082_CR12","unstructured":"Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, updated June 27, 2024. https:\/\/www.cdc.gov\/vaccines\/schedules\/downloads\/adult\/adult-combined-schedule.pdf."},{"key":"1082_CR13","unstructured":"European Centre for Disease Prevention and Control. Vaccine Scheduler; cited February 20, 2024. https:\/\/vaccine-schedule.ecdc.europa.eu\/."},{"key":"1082_CR14","unstructured":"World Health Organization. WHO Recommendations for Routine Immunization - Summary Tables 2023; cited February 20, 2024. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/immunization_schedules\/table_1_feb_2023_english.pdf?sfvrsn=c7de0e97_11&download=true."},{"key":"1082_CR15","unstructured":"Centers for Disease Control and Prevention. Immunization Schedules Adult Immunization Schedule Addendum (Updated February 29, 2024). https:\/\/www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult-schedule-addendum.html."},{"key":"1082_CR16","unstructured":"World Health Organization. COVID-19 Advice for the Public: Getting Vaccinated; cited February 20, 2024. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/covid-19-vaccines\/advice."},{"issue":"29","key":"1082_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","volume":"72","author":"M Melgar","year":"2023","unstructured":"Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793\u2013801.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1082_CR18","unstructured":"National Institutes of Health. COVID-19 Treatment Guidelines Special Considerations in People Who Are Immunocompromised 2024, updated February 29, 2024. https:\/\/www.covid19treatmentguidelines.nih.gov\/special-populations\/immunocompromised\/."},{"issue":"2","key":"1082_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41435-023-00219-6","volume":"25","author":"TR Muller","year":"2024","unstructured":"Muller TR, Buggert M. Boosting SARS-CoV-2 immunity in immunocompromised individuals. Genes Immun. 2024;25(2):168\u20139.","journal-title":"Genes Immun"},{"key":"1082_CR20","unstructured":"European Centre for Disease Prevention and Control. Seasonal Influenza Vaccination and Antiviral Use in EU\/EEA Member States; cited February 20, 2024. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/seasonal-influenza-antiviral-use-2018.pdf."},{"key":"1082_CR21","unstructured":"European Centre for Disease Prevention and Control. Seasonal Influenza Vaccination Recommendations and Coverage Rates in EU\/EEA Member States 2023, updated October 2023. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Seasonal-flu-vacc-recs-coverage-rates-EU-EEA.pdf."},{"issue":"51","key":"1082_CR22","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.15585\/mmwr.mm7251a4","volume":"72","author":"CL Black","year":"2023","unstructured":"Black CL, Kriss JL, Razzaghi H, Patel SA, Santibanez TA, Meghani M, et al. Influenza, updated COVID-19, and respiratory syncytial virus vaccination coverage among adults\u2014United States, fall 2023. MMWR Morb Mortal Wkly Rep. 2023;72(51):1377\u201382.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1082_CR23","unstructured":"Centers for Disease Control and Prevention. Respiratory Illnesses Vaccination Trends - Adults 2024, updated March 22, 2024. https:\/\/www.cdc.gov\/respiratory-viruses\/data-research\/dashboard\/vaccination-trends-adults.html."},{"key":"1082_CR24","unstructured":"World Health Organization. Managing Seasonal Vaccination Policies and Coverage in the European Region; cited February 20, 2024. https:\/\/www.who.int\/europe\/activities\/managing-seasonal-vaccination-policies-and-coverage-in-the-european-region."},{"key":"1082_CR25","unstructured":"European Centre for Disease Prevention and Control. Interim COVID-19 Vaccination Coverage in the EU\/EEA during the 2023\u201324 Season Campaigns 2024. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/interim-covid-19-vaccination-coverage-eueea-during-2023-24-season-campaigns."},{"key":"1082_CR26","unstructured":"Government of Canada. COVID-19 Vaccination: Vaccination Coverage, updated March 8, 2024. https:\/\/health-infobase.canada.ca\/covid-19\/vaccination-coverage\/#a5."},{"key":"1082_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102319","volume":"35","author":"C Vardavas","year":"2023","unstructured":"Vardavas C, Nikitara K, Aslanoglou K, Lagou I, Marou V, Phalkey R, et al. Social determinants of health and vaccine uptake during the first wave of the COVID-19 pandemic: a systematic review. Prev Med Rep. 2023;35: 102319.","journal-title":"Prev Med Rep"},{"key":"1082_CR28","doi-asserted-by":"publisher","DOI":"10.2196\/48466","volume":"10","author":"B Mahmood","year":"2024","unstructured":"Mahmood B, Adu P, McKee G, Bharmal A, Wilton J, Janjua NZ. Ethnic disparities in COVID-19 vaccine mistrust and receipt in British Columbia, Canada: population survey. JMIR Public Health Surveill. 2024;10: e48466.","journal-title":"JMIR Public Health Surveill"},{"issue":"6","key":"1082_CR29","doi-asserted-by":"publisher","first-page":"E1075","DOI":"10.9778\/cmajo.20230026","volume":"11","author":"M Guay","year":"2023","unstructured":"Guay M, Maquiling A, Chen R, Lavergne V, Baysac DJ, Dub\u00e9 \u00c8, et al. Racial disparities in COVID-19 vaccination in Canada: results from the cross-sectional Canadian Community Health Survey. CMAJ Open. 2023;11(6):E1075\u201382.","journal-title":"CMAJ Open"},{"issue":"29","key":"1082_CR30","doi-asserted-by":"publisher","first-page":"E1018","DOI":"10.1503\/cmaj.212147","volume":"194","author":"J Smylie","year":"2022","unstructured":"Smylie J, McConkey S, Rachlis B, Avery L, Mecredy G, Brar R, et al. Uncovering SARS-COV-2 vaccine uptake and COVID-19 impacts among first nations, Inuit and M\u00e9tis peoples living in Toronto and London, Ontario. CMAJ. 2022;194(29):E1018\u201326.","journal-title":"CMAJ"},{"issue":"1","key":"1082_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.anzjph.2024.100130","volume":"48","author":"GH Soares","year":"2024","unstructured":"Soares GH, Hedges J, Poirier B, Sethi S, Jamieson L. Deadly places: the role of geography in Aboriginal and Torres Strait Islander COVID-19 vaccination. Aust N Z J Public Health. 2024;48(1):100130.","journal-title":"Aust N Z J Public Health"},{"key":"1082_CR32","unstructured":"Australia PTU. COVID-19 Vaccinations 2024. https:\/\/phidu.torrens.edu.au\/social-health-atlases\/topic-atlas\/covid-vaccinations#aboriginal-and-torres-strait-islander-people."},{"issue":"2","key":"1082_CR33","doi-asserted-by":"publisher","DOI":"10.3201\/eid3002.230768","volume":"30","author":"O Eales","year":"2024","unstructured":"Eales O, Plank MJ, Cowling BJ, Howden BP, Kucharski AJ, Sullivan SG, et al. Key challenges for respiratory virus surveillance while transitioning out of acute phase of COVID-19 pandemic. Emerg Infect Dis. 2024;30(2):e230768.","journal-title":"Emerg Infect Dis"},{"key":"1082_CR34","unstructured":"European Centre for Disease Prevention and Control. Operational considerations for respiratory virus surveillance in Europe. Copenhagen; 2022. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/operational-considerations-respiratory-virus-surveillance-europe."},{"issue":"1","key":"1082_CR35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-020-20399-3","volume":"12","author":"S Pei","year":"2021","unstructured":"Pei S, Teng X, Lewis P, Shaman J. Optimizing respiratory virus surveillance networks using uncertainty propagation. Nat Commun. 2021;12(1):222.","journal-title":"Nat Commun"},{"issue":"14","key":"1082_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.15585\/mmwr.mm7214a1","volume":"72","author":"S Hamid","year":"2023","unstructured":"Hamid S, Winn A, Parikh R, Jones JM, McMorrow M, Prill MM, et al. Seasonality of respiratory syncytial virus\u2014United States, 2017\u20132023. MMWR Morb Mortal Wkly Rep. 2023;72(14):355\u201361.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1082_CR37","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ijid.2022.08.002","volume":"122","author":"SS Lee","year":"2022","unstructured":"Lee SS, Viboud C, Petersen E. Understanding the rebound of influenza in the post COVID-19 pandemic period holds important clues for epidemiology and control. Int J Infect Dis. 2022;122:1002\u20134.","journal-title":"Int J Infect Dis"},{"key":"1082_CR38","unstructured":"European Centre for Disease Prevention and Control. Survey on the Implementation of Integrated Surveillance of Respiratory Viruses with Pandemic Potential 2023, updated June 2022. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/survey-implementation-integrated-surveillance-respiratory-viruses-pandemic."},{"issue":"12","key":"1082_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208601","volume":"13","author":"C Betsch","year":"2018","unstructured":"Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Bohm R. Beyond confidence: development of a measure assessing the 5C psychological antecedents of vaccination. PLoS ONE. 2018;13(12):e0208601.","journal-title":"PLoS ONE"},{"issue":"6","key":"1082_CR40","doi-asserted-by":"publisher","first-page":"2127290","DOI":"10.1080\/21645515.2022.2127290","volume":"18","author":"AL Eiden","year":"2022","unstructured":"Eiden AL, Barratt J, Nyaku MK. Drivers of and barriers to routine adult vaccination: a systematic literature review. Hum Vaccin Immunother. 2022;18(6):2127290.","journal-title":"Hum Vaccin Immunother"},{"key":"1082_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12889-016-2784-8","volume":"16","author":"CJ Klett-Tammen","year":"2016","unstructured":"Klett-Tammen CJ, Krause G, Seefeld L, Ott JJ. Determinants of tetanus, pneumococcal and influenza vaccination in the elderly: a representative cross-sectional study on knowledge, attitude and practice (KAP). BMC Public Health. 2016;16:121.","journal-title":"BMC Public Health"},{"issue":"6","key":"1082_CR42","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3390\/ijerph14060665","volume":"14","author":"M Ganczak","year":"2017","unstructured":"Ganczak M, Gil K, Korzen M, Bazydlo M. Coverage and influencing determinants of influenza vaccination in elderly patients in a country with a poor vaccination implementation. Int J Environ Res Public Health. 2017;14(6):665.","journal-title":"Int J Environ Res Public Health"},{"issue":"44","key":"1082_CR43","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.1016\/j.vaccine.2019.09.037","volume":"37","author":"LM Teo","year":"2019","unstructured":"Teo LM, Smith HE, Lwin MO, Tang WE. Attitudes and perception of influenza vaccines among older people in Singapore: a qualitative study. Vaccine. 2019;37(44):6665\u201372.","journal-title":"Vaccine"},{"issue":"15","key":"1082_CR44","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1016\/j.vaccine.2023.02.047","volume":"41","author":"C Meyer","year":"2023","unstructured":"Meyer C, Goffe L, Antonopoulou V, Graham F, Tang MY, Lecouturier J, et al. Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England. Vaccine. 2023;41(15):2466\u201375.","journal-title":"Vaccine"},{"issue":"1","key":"1082_CR45","doi-asserted-by":"publisher","first-page":"2303796","DOI":"10.1080\/21645515.2024.2303796","volume":"20","author":"EM La","year":"2024","unstructured":"La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, et al. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2024;20(1):2303796.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"1082_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.vaccine.2018.12.031","volume":"37","author":"LP Hurley","year":"2019","unstructured":"Hurley LP, Allison MA, Kim L, O\u2019Leary ST, Crane LA, Brtnikova M, et al. Primary care physicians\u2019 perspectives on respiratory syncytial virus (RSV) disease in adults and a potential RSV vaccine for adults. Vaccine. 2019;37(4):565\u201370.","journal-title":"Vaccine"},{"issue":"1","key":"1082_CR47","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/idr16010010","volume":"16","author":"D Ponticelli","year":"2024","unstructured":"Ponticelli D, Losa L, Antonazzo IC, Zampella A, Di Marino F, Mottola G, et al. Respiratory syncytial virus (RSV) and intention to recommend RSV vaccination: a cross-sectional survey of cardiologists and cardiac nurses in Southern Italy. Infect Dis Rep. 2024;16(1):128\u201341.","journal-title":"Infect Dis Rep"},{"issue":"34","key":"1082_CR48","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","volume":"33","author":"NE MacDonald","year":"2015","unstructured":"MacDonald NE, Hesitancy SWGV. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161\u20134.","journal-title":"Vaccine"},{"issue":"1","key":"1082_CR49","doi-asserted-by":"publisher","first-page":"2176083","DOI":"10.1080\/21645515.2023.2176083","volume":"19","author":"LR Biasio","year":"2023","unstructured":"Biasio LR, Zanobini P, Lorini C, Monaci P, Fanfani A, Gallinoro V, et al. COVID-19 vaccine literacy: a scoping review. Hum Vaccin Immunother. 2023;19(1):2176083.","journal-title":"Hum Vaccin Immunother"},{"issue":"11","key":"1082_CR50","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3390\/vaccines9111348","volume":"9","author":"JYH Voo","year":"2021","unstructured":"Voo JYH, Lean QY, Ming LC, Md Hanafiah NH, Al-Worafi YM, Ibrahim B. Vaccine knowledge, awareness and hesitancy: a cross sectional survey among parents residing at Sandakan District, Sabah. Vaccines (Basel). 2021;9(11):1348.","journal-title":"Vaccines (Basel)."},{"issue":"7","key":"1082_CR51","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/vaccines10071038","volume":"10","author":"W Ekezie","year":"2022","unstructured":"Ekezie W, Awwad S, Krauchenberg A, Karara N, Dembi\u0144ski \u0141, Grossman Z, et al. Access to vaccination among disadvantaged, isolated and difficult-to-reach communities in the WHO European Region: a systematic review. Vaccines (Basel). 2022;10(7):1038.","journal-title":"Vaccines (Basel)"},{"key":"1082_CR52","unstructured":"Centers for Disease Control and Prevention. Healthcare Providers\/Professionals Current Vaccine Shortages & Delays 2024, updated February 26, 2024. https:\/\/www.cdc.gov\/vaccines\/hcp\/clinical-resources\/shortages.html."},{"issue":"12","key":"1082_CR53","doi-asserted-by":"publisher","first-page":"918, 20, 23, 27","DOI":"10.3949\/ccjm.71.12.918","volume":"71","author":"SB Mossad","year":"2004","unstructured":"Mossad SB. Coping with the influenza vaccine shortage. Cleve Clin J Med. 2004;71(12):918, 20, 23, 27.","journal-title":"Cleve Clin J Med"},{"key":"1082_CR54","unstructured":"Centers for Disease Control and Prevention. Emergency Preparedness and Response Limited Availability of Nirsevimab in the United States\u2014Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023\u20132024 Respiratory Virus Season 2023, updated October 23, 2023. https:\/\/emergency.cdc.gov\/han\/2023\/han00499.asp.."},{"issue":"11","key":"1082_CR55","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jamapediatrics.2023.3260","volume":"177","author":"UR Essien","year":"2023","unstructured":"Essien UR, Dusetzina SB. Cost-related barriers and ensuring equitable access to vaccines in the US. JAMA Pediatr. 2023;177(11):1117\u20138.","journal-title":"JAMA Pediatr"},{"key":"1082_CR56","unstructured":"World Health Organization. Immunization Agenda 2030. A Global Strategy to Leave No One Behind 2023; cited February 20, 2024. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/strategy\/ia2030\/ia2030-draft-4-wha_b8850379-1fce-4847-bfd1-5d2c9d9e32f8.pdf?sfvrsn=5389656e_69&download=true."},{"key":"1082_CR57","unstructured":"Centers for Disease Control and Prevention. CDC Global Immunization Strategic Framework 2023, updated April 20, 2023. https:\/\/www.cdc.gov\/globalhealth\/immunization\/framework\/index.html."},{"issue":"9","key":"1082_CR58","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3390\/vaccines9091016","volume":"9","author":"A Domnich","year":"2021","unstructured":"Domnich A, Grassi R, Fallani E, Spurio A, Bruzzone B, Panatto D, et al. Changes in attitudes and beliefs concerning vaccination and influenza vaccines between the first and second COVID-19 pandemic waves: a longitudinal study. Vaccines (Basel). 2021;9(9):1016.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"1082_CR59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/vaccines11010016","volume":"11","author":"N Tzenios","year":"2022","unstructured":"Tzenios N, Tazanios ME, Chahine M. Combining influenza and COVID-19 booster Vaccination strategy to improve vaccination uptake necessary for managing the health pandemic: a systematic review and meta-analysis. Vaccines (Basel). 2022;11(1):16.","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"1082_CR60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/vaccines12020216","volume":"12","author":"RCA Achterbergh","year":"2024","unstructured":"Achterbergh RCA, McGovern I, Haag M. Co-administration of influenza and COVID-19 vaccines: policy review and vaccination coverage trends in the European Union, UK, US, and Canada between 2019 and 2023. Vaccines (Basel). 2024;12(2):216.","journal-title":"Vaccines (Basel)"},{"key":"1082_CR61","unstructured":"Centers for Disease Control and Prevention. Influenza (Flu) Getting a Flu Vaccine and other Recommended Vaccines at the Same Time 2023, updated December 8, 2023. https:\/\/www.cdc.gov\/flu\/prevent\/coadministration.htm."},{"issue":"4","key":"1082_CR62","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","volume":"10","author":"R Izikson","year":"2022","unstructured":"Izikson R, Brune D, Bolduc JS, Bourron P, Fournier M, Moore TM, et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: a phase 2, randomised, open-label study. Lancet Respir Med. 2022;10(4):392\u2013402.","journal-title":"Lancet Respir Med"},{"issue":"10318","key":"1082_CR63","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","volume":"398","author":"R Lazarus","year":"2021","unstructured":"Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021;398(10318):2277\u201387.","journal-title":"Lancet"},{"issue":"2","key":"1082_CR64","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","volume":"10","author":"S Toback","year":"2022","unstructured":"Toback S, Galiza E, Cosgrove C, Galloway J, Goodman AL, Swift PA, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(2):167\u201379.","journal-title":"Lancet Respir Med"},{"key":"1082_CR65","unstructured":"Harris DA, Chachlani P, Hayes KN, McCarthy EP, Wen KJ, Deng Y, et al. COVID-19 and influenza vaccine coadministration among older U.S. adults. Am J Prev Med. 2024:S0749-3797(24)00067-9."},{"key":"1082_CR66","unstructured":"Centers for Disease Control and Prevention. Vaccines for Your Children Combination Vaccines 2019, updated August 1, 2019. https:\/\/www.cdc.gov\/vaccines\/parents\/why-vaccinate\/combination-vaccines.html#print."},{"issue":"6","key":"1082_CR67","doi-asserted-by":"publisher","first-page":"2131166","DOI":"10.1080\/21645515.2022.2131166","volume":"18","author":"C Janssen","year":"2022","unstructured":"Janssen C, Mosnier A, Gavazzi G, Combadiere B, Crepey P, Gaillat J, et al. Coadministration of seasonal influenza and COVID-19 vaccines: a systematic review of clinical studies. Hum Vaccin Immunother. 2022;18(6):2131166.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1082_CR68","doi-asserted-by":"publisher","first-page":"2195786","DOI":"10.1080\/21645515.2023.2195786","volume":"19","author":"P Bonanni","year":"2023","unstructured":"Bonanni P, Steffen R, Schelling J, Balaisyte-Jazone L, Posiuniene I, Zatonski M, et al. Vaccine co-administration in adults: an effective way to improve vaccination coverage. Hum Vaccin Immunother. 2023;19(1):2195786.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"1082_CR69","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1097\/INF.0000000000003499","volume":"41","author":"J Tuckerman","year":"2022","unstructured":"Tuckerman J, Kaufman J, Danchin M. Effective approaches to combat vaccine hesitancy. Pediatr Infect Dis J. 2022;41(5):e243\u20135.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"1082_CR70","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13643-022-01941-4","volume":"11","author":"P Singh","year":"2022","unstructured":"Singh P, Dhalaria P, Kashyap S, Soni GK, Nandi P, Ghosh S, et al. Strategies to overcome vaccine hesitancy: a systematic review. Syst Rev. 2022;11(1):78.","journal-title":"Syst Rev"},{"issue":"20","key":"1082_CR71","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1016\/j.vaccine.2022.03.039","volume":"40","author":"K Wells","year":"2022","unstructured":"Wells K, Moore KL, Bednarczyk R. Supporting immunization programs to address COVID-19 vaccine hesitancy: recommendations for national and community-based stakeholders. Vaccine. 2022;40(20):2819\u201322.","journal-title":"Vaccine"},{"issue":"3","key":"1082_CR72","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.3390\/ijms24032700","volume":"24","author":"V Gote","year":"2023","unstructured":"Gote V, Bolla PK, Kommineni N, Butreddy A, Nukala PK, Palakurthi SS, et al. A comprehensive review of mRNA vaccines. Int J Mol Sci. 2023;24(3):2700.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1082_CR73","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/vaccines9040390","volume":"9","author":"F Kowalzik","year":"2021","unstructured":"Kowalzik F, Schreiner D, Jensen C, Teschner D, Gehring S, Zepp F. mRNA-based vaccines. Vaccines (Basel). 2021;9(4):390.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"1082_CR74","doi-asserted-by":"publisher","first-page":"2027160","DOI":"10.1080\/21645515.2022.2027160","volume":"18","author":"I Mohammed","year":"2022","unstructured":"Mohammed I, Nauman A, Paul P, Ganesan S, Chen KH, Jalil SMS, et al. The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. Hum Vaccin Immunother. 2022;18(1):2027160.","journal-title":"Hum Vaccin Immunother"},{"key":"1082_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714170","volume":"12","author":"N Sharif","year":"2021","unstructured":"Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12: 714170.","journal-title":"Front Immunol"},{"key":"1082_CR76","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijid.2021.11.009","volume":"114","author":"C Zheng","year":"2022","unstructured":"Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis. 2022;114:252\u201360.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"1082_CR77","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1038\/s41467-023-39376-7","volume":"14","author":"IT Lee","year":"2023","unstructured":"Lee IT, Nachbagauer R, Ensz D, Schwartz H, Carmona L, Schaefers K, et al. Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat Commun. 2023;14(1):3631.","journal-title":"Nat Commun"},{"key":"1082_CR78","unstructured":"Moderna Inc. Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease 2023. https:\/\/investors.modernatx.com\/news\/news-details\/2023\/Moderna-Expands-the-Field-of-mRNA-Medicine-with-Positive-Clinical-Results-Across-Cancer-Rare-Disease-and-Infectious-Disease\/default.aspx."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-01082-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-01082-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T13:04:23Z","timestamp":1736600663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-01082-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":78,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1082"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-01082-2","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stefania Maggi has speaking engagements\/honoraria\/research grants from: Moderna, Merck, Pfizer, Sanofi, GSK, Janssen, and BioNTech. Rachel Dawson is an employee of Moderna, Inc., and holds stock\/stock options in the company. Odile Launay has speaking engagements\/honoraria\/research grants from: Moderna, Merck, Pfizer, Sanofi, GSK, and Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}